Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0052W HIGH $3.26
Volume
131.97 K
Value Traded
484.85 K
Short % Float
4.65%
Days to Cover
10.6
-7.21%Week
-21.97%1 Month
-54.22%3 Month
-53.6%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
37.01 M
EPS (TTM)
0.20
P/E Ratio
5.04
Ent. Value
153.96 M
Total Shares
35.93 M
Float Shares
23.30 M
Insiders
18.76%
Institutions
61.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BTMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Biote Corp. Class A Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biote Corp. Class A Common Stock
88Total events
1Upcoming
9Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 1
TBD
T2Patent Granted
Subscribe to view catalyst details
Event history 50
▲PK PD DataClinical Data
Double-blinded PK study demonstrates faster absorption with oral dissolvable strip
▲Partnership / LicenseCorporate
Developing partnerships and distribution channels in Southeast Asia, Latin America, Middle East
▲Manufacturing MilestoneCMC / Inspection
Nine ISS investigations completed for artificial retina manufacturing
age-related macular degeneration, retinitis pigmentosasource ↗
▲Product LaunchPost-Market
BioTech Funding Portal launched as SEC-registered Reg CF portal for life science companies
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results Release and Conference Call
●Quarterly UpdateCorporate
Reiterated 2025 financial guidance: revenue above $190M, adjusted EBITDA above $50M
▲Management ChangeCorporate
Amended settlement with Dr. Gary Donovitz in November 2025 to repurchase remaining shares
▼RecallCMC / Inspection
Voluntary recall of specific lots of hormone pellets shipped by Asteria Health
▲Equity OfferingCorporate
Repurchased approximately one million shares of Class A common stock in Q3 2025
▲Management ChangeCorporate
Amended settlement with Marci Donovitz on September 26, 2025 to repurchase remaining shares
◆Restructuring LayoffsCorporate
Organizational restructuring announced to drive sustainable growth
●Restructuring LayoffsCorporate
Biote initiated organizational restructuring in early May 2025
◆Management ChangeCorporate
Terry Weber retiring as CEO and Director, effective February 1, 2025; Bret Christensen named CEO and Director effective same date
●Timing GuidancePresentation
Biote revises fiscal 2025 revenue guidance to >$190M and Adjusted EBITDA guidance to >$50M
◆Runway Guidance UpdateCorporate
2025 financial outlook maintained: revenue $202-208M, adjusted EBITDA $59-64M
●Quarterly UpdateCorporate
Q1 2025 revenue expected slightly higher, adjusted EBITDA ~5% lower vs Q1 2024
◆Timing GuidanceBioteRxPresentation
BioteRx further expansion planned through remainder of 2024 and into 2025
preventative wellness, sexual health, weight losssource ↗
▼Quarterly UpdateCorporate
Biote revises 2024 full-year revenue guidance to $197-$201M and Adjusted EBITDA to $58-$61M
●Quarterly UpdateCorporate
Management reiterates 2024 financial guidance for revenue and Adjusted EBITDA
▲Product LaunchBioteRxPost-Market
BioteRx launched and rolled out to approximately 600 clinics
preventative wellness, sexual health, weight losssource ↗
▼Equity OfferingCorporate
Share repurchases from Dr. Gary S. Donovitz and Marci M. Donovitz settlements
◆Equity OfferingCorporate
Agreement to repurchase 8.3 million shares and cancel 4.0 million earnout shares for $60 million
▲IP Litigation RulingIP / Competition
Definitive settlement reached with founder Dr. Gary S. Donovitz on April 23, 2024
●Quarterly UpdateCorporate
Direct-to-patient distribution of nutraceutical products expected to begin in Q2 2024
▲Restructuring LayoffsCorporate
Agreement to resolve litigation and repurchase founder's shares
▲Product LaunchBioteRxPost-Market
Phased launch of BioteRx hormone and therapeutic wellness products
hormone optimization and therapeutic wellnesssource ↗
▲Quarterly UpdateCorporate
Phased launch of new therapeutic wellness products on proprietary technology platform commencing Q1 2024
Past FDA Catalysts and PDUFA Decisions
How BTMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BTMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Beer Marc DDirector, Officer (Executive Chairman) | Buy | 16,000 239,744 held | $1.55 | 08/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BTMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BTMD for Q2 2026. | ||||
BTMD Institutional Ownership Trends
BTMD Short Interest
Shares sold short, counted twice a month.
4.65%
Short % of Float
of tradable shares sold short
1.1M
Shares Sold Short
-15.4% vs prior count
10.6 Very high
Days to Cover
trading days of normal volume to buy every short share back
102.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BTMD ranks across every disease it competes in
Competitive Position is a premium feature
See how BTMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBTMD News
-BTMD
Oct 21, 2026▼ -3.7%today
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
Biote Corp. announced it will release its third quarter financial results on November 4, 2026. The results will be shared after market close, followed by a conference call at 5:00 p.m. ET. This event aims to provide insights into the company's financial performance.
Read more →-BTMD
Sep 17, 2026BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies
BioTech Social Inc. has announced the formation of an advisory board to enhance financial innovation for life science companies. This board will help address the critical funding challenges faced during the development of new therapies. The company aims to improve access to capital through its BioTech Funding Portal, which allows companies to raise funds via Regulation Crowdfunding.
Read more →-BTMD
Sep 15, 2026Biotech Innovator Solfarcos Brings Capabilities Behind K18 Development to New Markets
Solfarcos, a biotechnology company, is expanding its operations to the United States. The firm aims to establish partnerships with U.S. companies to bring its innovative peptide and protein-based solutions to a broader market. This initiative is part of Solfarcos's strategy to enhance premium, science-led products across various applications beyond cosmetics.
Read more →-BTMD
Aug 31, 2026BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem
BIOTECanada has announced the winners of the 2026 Gold Leaf Awards, which honor exceptional leadership and innovation within Canada's biotechnology sector. This annual event has been recognizing influential individuals and organizations for over 20 years, showcasing their contributions to advancing Canadian innovation on a global scale. The awards reflect the depth of talent and impact within the industry.
Read more →-BTMD
Aug 5, 2026▼ -27.9%on this news
Biote Reports Second Quarter 2026 Financial Results
Biote, a leader in hormone optimization, announced its financial results for Q2 2026. The company highlighted significant progress in its strategic initiatives, which are expected to lead to sustainable revenue growth. CEO Bob Peterso emphasized the improvements made over the past year, reflecting a positive outlook for the company's future.
Read more →-BTMD
Jul 27, 2026Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform
InstaMed® Pharmaceuticals has appointed Tracy Gibbs, PhD, as CEO ahead of the launch of its non-injectable peptide platform. The company will introduce five new oral dissolving peptide products on August 3, 2026, backed by successful pharmacokinetic study results and nine pending patents. This innovative platform aims to enhance patient access to peptide therapies by eliminating the need for injections.
Read more →-BTMD
Jul 22, 2026Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
Biote Corp. has announced that it will release its second quarter financial results on August 5, 2026, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results. This event highlights the company's commitment to keeping stakeholders informed.
Read more →-BTMD
Jul 14, 2026Biotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphia
The Emily Whitehead Foundation will host its 2026 Believe Ball in Philadelphia, featuring John F. Crowley as the keynote speaker. The event aims to bridge the gap between patients and industry leaders in advanced therapies, particularly CAR T-cell therapy. It serves as a fundraiser to support patients affected by cancer and rare diseases, celebrating stories of hope and innovation.
Read more →-BTMD
Jul 1, 2026▲ +5.3%on this news· ran to +19% by day 3
Biotech Startup Turns to Space to Manufacture Artificial Retinas for Treating Blindness
LambdaVision, a biotech startup, is utilizing microgravity on the ISS to manufacture artificial retinas aimed at restoring vision for those with macular degeneration. The unique environment allows for improved material properties and production efficiency. The company plans to continue its research and production in future commercial space stations after the ISS retirement.
Read more →-BTMD
Jun 22, 2026BIOTECanada Opens Canada Pavilion at BIO 2026 Amid Major Policy Momentum for Canadian Biotech
BIOTECanada has announced the opening of the Canada Pavilion at BIO 2026. This initiative comes at a time when there is significant policy momentum supporting the Canadian biotech sector. The pavilion aims to showcase Canadian innovations and foster international collaborations within the industry.
Read more →-BTMD
Jun 1, 2026▲ +5.5%on this news· ran to +18% by day 3
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Biote has announced the appointment of Komal Bajaj, MD, MS as its new Chief Medical Officer. This leadership change is part of the company's strategy to enhance its medical expertise. Dr. Bajaj brings significant experience in the biopharma sector to her new role.
Read more →-BTMD
May 28, 2026Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
Biote has appointed Bob Peterson, the current Chief Financial and Chief Business Officer, as the Interim CEO. This leadership change comes as the company seeks to navigate its strategic direction. Further details regarding the transition and its implications for the company have not been disclosed.
Read more →-BTMD
May 6, 2026Biote Reports First Quarter 2026 Financial Results
Biote has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. Specific details regarding revenue, expenses, and other financial metrics were not disclosed in the text provided.
Read more →-BTMD
Apr 22, 2026Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
Biote has announced the scheduling of its financial results release for the first quarter of 2026, along with a conference call to discuss these results. This event aims to provide stakeholders with insights into the company's financial performance and future outlook. Further details regarding the call will be shared closer to the date.
Read more →-BTMD
Apr 3, 2026Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered "forward-looking statements" within the meaning of t
Biote Holdings presented forward-looking statements regarding its financial performance and growth strategy. The projections include a revenue estimate of $192.2 million for 2025 and highlight the expertise of over 9,200 Biote-certified practitioners. However, the company acknowledges multiple risks, including reliance on third-party partners and the competitive landscape, which may affect its business operations. These statements are based on certain assumptions and are not guarantees of future results.
Read more →-BTMD
Mar 11, 2026Biote Reports Fourth Quarter and Full Year 2025 Financial Results Executing efficiently on strategic priorities
Biote (NASDAQ: BTMD) has reported its fourth quarter and full year 2025 financial results, revealing a revenue of $46.4 million for the last quarter, which is a 6.9% decline year-over-year. The company highlights continued expansion in dietary supplements revenue and a projected return to procedure revenue growth in the latter half of 2026. Despite facing a decrease in procedure revenue by 13.0%, Biote's management remains optimistic about future investments in sales and technology capabilities. The strategic focus aims to enhance patient health and drive sustainable growth moving forward.
Read more →-BTMD
Feb 26, 2026Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
Biote Corp. has announced the release date for its fourth quarter and full year financial results, scheduled for March 11, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results. The company emphasizes its commitment to hormone replacement therapy and healthy aging solutions, showcasing its innovative approach in the healthcare sector.
Read more →-BTMD
Nov 5, 2025Biote Reports Third Quarter 2025 Financial Results Continued progress against strategic priorities
Biote Corp. reported its financial results for the third quarter of 2025, noting a revenue of $48.0 million, a 6.7% decrease from the previous year. Despite challenges, the company highlighted an improved gross profit margin of 71.8% and successfully repurchased approximately one million shares. Net income declined to $9.2 million, reflecting lower sales and higher operating expenses. The company reiterated its financial guidance for 2025, expecting revenue to exceed $190 million and adjusted EBITDA to surpass $50 million.
Read more →-BTMD
Aug 6, 2025▼ -7.4%on this news· ran to -32% by day 3
Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion
Biote reported its financial results for Q2 2025, marking a revenue of $48.9 million, slightly decreasing from $49.2 million a year prior. The company highlighted strong growth in dietary supplement sales, leading to an improved gross profit margin of 71.6%. Notably, Biote's organizational restructuring aims to drive sustainable growth, although procedure revenue has decreased by 8.4%. The company adjusted its 2025 revenue guidance to a range above $190 million, reflecting current market challenges and proactive changes in strategy.
Read more →-BTMD
Jun 9, 2025Biote Names Rich Barrera to Board of Directors
Biote Corp. has appointed Rich Barrera to its Board of Directors, effective immediately. Barrera, the founder and CEO of Roystone Capital, has extensive experience in investment management and is recognized for his significant background in finance. His alignment with Biote's growth strategy is seen as beneficial as the company continues to expand its personalized hormone optimization and wellness solutions. This decision comes as Biote aims to enhance its market position in the preventive healthcare industry.
Read more →About Biote Corp. Class A Common Stock
Headquarters1875 W. WALNUT HILL LN #100, IRVING, TX, 75038
BIOPHARMAWATCH ELITE PLUS
Trade the next BTMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime